|
|
|
|
|
|
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
A Phase 1a Open-Label, Single Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered PYC-001 in Participants With Confirmed OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy
A First-in-Human multi-centre, prospective, Phase1a, Single Ascending Dose (SAD) interventional study of PYC-001 in participants with confirmed OPA1 mutation (haploinsufficiency) associated ADOA.
100 项与 OPA1 x VEGF x Tubulin 相关的临床结果
100 项与 OPA1 x VEGF x Tubulin 相关的转化医学
0 项与 OPA1 x VEGF x Tubulin 相关的专利(医药)